NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Rein Therapeutics Inc. (RNTX) Stock Analysis

Rein Therapeutics Inc. (RNTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RNTX

$0.89

+$0.05 (+5.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RNTX with… →

RNTX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.92
Previous Close
$0.84
Day's Range
0.85–0.92
52-Week Range
0.69–2.18
Volume
984.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.37
Valuation
Market Cap
$76.70M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.68
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$49.87M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
86.27M
1-Year Return
−34.87%
Dividend and dates
Avg Volume
500.39K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RNTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−23.36%
2025−49.57%
2024−24.57%
2023+28.65%
2022−78.95%
2021−45.87%
2020+81.50%
2019−31.79%
2018−92.03%
2017 (partial year)−2.41%

As of September 4, 2026.

RNTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$49.87M—
2024$0.00−$62.88M—
2023$0.00−$15.73M—
2022$0.00−$27.33M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$21.93M−$49.87M—
2024$0.00—−$28.11M−$62.88M—
2023$0.00—−$15.35M−$15.73M—
2022$0.00—−$27.65M−$27.33M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RNTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricRNTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Rein Therapeutics Inc. (RNTX) is capitalised at $76.70M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 10.

RNTX last closed at $0.89 on September 4, 2026. That is +$0.05 (+5.33%) against the previous close. The 52-week range on file runs from $0.69 to $2.18. The latest close sits 28.1% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $49.87M. Profit margin runs at 0%. Trailing earnings per share are −1.68.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is −34.87%. Across 5 years the annualized return works out at −48.01%. Beta against the wider market is reported at 1.37. Annualized volatility over the trailing 9 years is 111.54%.

Growth & Income

The record shows no dividend for RNTX.

The strongest complete calendar year on file is 2020 at +81.50%; the weakest is 2018 at −92.03%. Of the 8 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −23.36% year to date.

Peer Comparison

Rein Therapeutics Inc. (RNTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rein Therapeutics Inc. RNTX $76.70M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Rein Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Rein Therapeutics Inc.

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.

Visit website →